FDA Reviewing Information on Fosamax-Related Fractures

In a follow-up piece to Monday evening's report on femur fractures related to Fosamax (alendronate), ABC World News (3/9, story 4, 2:20, Sawyer) reported that ABC's Richard Besser, MD, interviewed FDA Deputy Commissioner Joshua Sharfstein, MD, asking him if now is the time for the agency "to send out a notice to physicians to be on the lookout for this" problem. Sharfstein stated that the FDA currently "does not feel a warning on this is justified, but we are continually re-evaluating that as we get more information." At the end of the piece, Besser voiced concerned that the FDA's "threshold is too high. I think to send a letter to doctors would show that they take this seriously and would to allow them to get the data they need to make a decision."